Small-molecule oncology drugs have advanced significantly in a short period of time. Their regulatory pathways differ from non-oncology drugs and may benefit from a streamlined process. Understanding these regulatory quirks may be key to bringing new small-molecule oncology drugs to market faster. https://hubs.li/Q039gD-w0 #oncology #smallmoleculedrugs #drugresearch
WuXi AppTec, Laboratory Testing Division
制药业
Plainsboro，NJ 5,248 位关注者
Your success is our success.
关于我们
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated.“ Our state-of-the-art Laboratory Testing Division in New Jersey provides leading bioanalytical & drug metabolism contract research services to a global customer base of pharmaceutical, biotech & agrochemical firms. Our bioanalytical services support a wide range of compounds-small & large molecules, new modalities including oligonucleotides, ADC, bispecific antibodies & more-from discovery to preclinical IND-enabling & regulated clinical studies. Capabilities include LC-MS/MS & immunochemistry platforms for GLP & non-GLP & customized Central Laboratory services to facilitate global clinical studies. Our comprehensive drug metabolism services are tailored to support the entire drug development cycle, from early discovery through IND-enabling to late-stage clinical development. Capabilities include in vivo pharmacokinetics, in vitro ADME, in vitro & in vivo biotransformation, & non-clinical radiolabel ADME (mass balance & QWBA).
- 网站
-
https://labtesting.wuxiapptec.com/
WuXi AppTec, Laboratory Testing Division的外部链接
- 所属行业
- 制药业
- 规模
- 201-500 人
- 总部
- Plainsboro，NJ
- 类型
- 上市公司
- 创立
- 1987
- 领域
- ADME、DMPK、bioanalysis、drug metabolism、animal health和agrochemical
地点
WuXi AppTec, Laboratory Testing Division员工
-
Virginia Pate Whitaker
Associate Director, Laboratory Operations at WuXi AppTec
-
Kristin Peterson
Director, Business Development, Western US Region and APAC at WuXi AppTec
-
Keith Ciccaglione
Scientist II at WuXi AppTec, Laboratory Testing Division, New Jersey site
-
TJ Sigler
Executive Director, Head of International Sales & Marketing | Laboratory Testing Division at WuXi AppTec
动态
-
The Bioanalytical Challenges of Fusion Proteins – Solved! Fusion proteins offer extended half-life, multi-target functionality, and innovative therapeutic potential, but their bioanalytical complexity requires cutting-edge solutions. Key challenges include: ? Ensuring accurate PK and immunogenicity assessments ? Overcoming matrix interferences in ELISA & MSD platforms ? Understanding multi-domain immunogenic responses How can we optimize bioanalytical strategies for fusion protein drugs? Our latest blog has the answers. Check it out now! https://hubs.li/Q03bZmz60 #FusionProteins #PKAnalysis #ImmunogenicityTesting #MSD #ELISA #Biopharmaceuticals
-
Join us at WRIB 2025! ?? Exciting news! WuXi AppTec is heading to WRIB 2025 – the premier global platform for bioanalytical, biomarkers, and immunogenicity discussions! At WuXi AppTec, we are committed to advancing bioanalysis with cutting-edge solutions for small and large molecules, oligonucleotides, ADCs, and more. Join us to explore how our high-throughput platforms, automation, and regulatory expertise can support your drug development journey. ?? Where: Booth #44 ?? When: April 7-11, 2025 ?? Let’s connect! Visit our booth or schedule a meeting with our experts #WRIB2025 #Bioanalysis #Biomarkers #DrugDevelopment
-
-
Drug solubility testing offers valuable insights during different stages of drug discovery and development. ??Read more for an overview of each stage: https://hubs.li/Q03cyC2W0 #solubility #adme #dmpk #drugdevelopment
-
-
Oligonucleotide drugs are evolving fast—but are your bioanalytical methods keeping up? Discover how advanced tools can simplify preclinical hurdles and deliver reliable results. https://hubs.li/Q03cyYwL0 #DrugDevelopment #Bioanalysis #Oligonucleotides #LBAs #DMPK
-
-
The journey of oligonucleotide drugs, from the first ASO approval in 1998 to today’s innovations, is nothing short of inspiring. Yet, their success hinges on mastering one critical factor: immunogenicity. Our latest blog dives deep into this challenge, covering: ? Key considerations for immunogenicity assessment. ? Delivery innovations and their impact on immune response. ? Advanced detection methods like the MSD platform. For researchers and developers in biopharma, this is a must-read to stay ahead in this evolving landscape. Read more: https://hubs.li/Q037Nf040 #Oligonucleotides #Immunogenicity #Bioanalysis #BiotechInnovation #PharmaInsights
-
Proteolysis Targeting Chimeras (PROTACs) are among the most exciting drugs in development, capable of degrading disease-causing proteins previously thought undruggable. But their complexity presents unique challenges—poor bioavailability, species-specific E3 ligase expression, unpredictable PK/PD profiles, and potential drug-drug interactions. How can developers overcome these hurdles and unlock the full potential of PROTACs? Here’s a look at the most common preclinical challenges and the strategies to address them. https://hubs.li/Q03cyBZY0 #drugdevelopment #dmpk #bioanalysis #protac #innovation
-
-
The SOT Annual Meeting & ToxExpo is ending soon! Visit with WuXi AppTec‘s experts at our Booth 1133, and be sure to check out our session. https://hubs.li/Q039rGr70
-
Small molecule drugs are the most common type of therapeutic on the market … but that doesn’t mean they are easy to develop. Small molecule preclinical testing is still a rigorous, required process that helps researchers understand how they behave in and out of the body – before they get to humans. In this guide, we cover everything you need to know about small molecule preclinical testing. https://hubs.li/Q03bZy640
-
Tomorrow at the SOT Annual Meeting & ToxExpo stop by our Booth 1133 and meet with WuXi AppTec‘s experts. Don’t miss these events. https://hubs.li/Q039rtSY0